

From Targeted Testing To Targeted Analysis: The Era of Comprehensive Clinical Genomics Analysis Is Coming

Y. Hongxing¹, H. Yanda²

Translational Medicine Research Center, Beijing Lu Daopei Institute of Hematology, Beijing, China^{1,2}



Abstract— With the generally use of cutting-edge sequencing (NGS) innovation in facility and the advancement of atomic systems look into in tumor, an ever-increasing number of sub-atomic markers have been recognized and utilized in clinical finding and treatment choices [1-4]. Discovery of handfuls or several qualities by focused sequencing has been generally utilized in the determination and treatment of different oncological and hereditary ailments, and reports of genomics examination dependent on entire exome sequencing (WES), entire genome sequencing (WGS), and transcriptome sequencing (RNA-seq) is additionally essentially expanded.

Keywords—Genetics, Genes.

1. Introduction

With the noteworthy reduction of expense and the improvement of diagnostic abilities, the utilization of WES, WGS and RNA-seq expanded bit by bit which gives increasingly far reaching hereditary data. Contrasted and customary therapeutic testings, genomics examination brings new ideas and difficulties. Conventional restorative testings (natural chemistry, immunology and focused on sequencing, and so forth.) essentially have a place with focused testing that require the assignment of a predetermined number of targets and relating tests which are relied upon to be pertinent to the sickness or phenotype. Hereditary testing is the first to continue with a methodologically complete omics-based investigation that covers the genuine entire of genome, exome and transcriptome instead of explicit targets. In any case, the gigantic measure of information produced by the omics sequencing (about 12G for 100 × WES information advertisement about 90G for 30 × WGS information) which carries an incredible test to the investigation and translation of data.

2. Understanding of the implication of genomics investigation

In past focused testing's, each test gives a constrained measure of data, and there is commonly no data excess. In any case, genomics testing is extraordinary; you can first acquire increasingly complete data in a single regard, and afterward remove rich data to control the determination and treatment of sicknesses from various edges as per the necessities. Genomics has brought progressive advances from "focused testing" to "focused examination" as far as testing and investigation modes.

We can utilize the genomics testing to investigate hereditary illness and hereditary inclining components of tumor, physical transformation, hereditary pharmacogenomics, minor histocompatibility antigens (mHAg), tumor neoantigen expectation just as telomere length and fanciful rate [5-11].


3. The period of far reaching clinical genomics investigation is coming

Presently the expense of WES is near the expense of focused sequencing of handfuls or many qualities, however the measure of data is enormously expanded. The upsides of omics testing and investigation are that it can give an assortment of data of clinical finding and treatment for patients by examination of

different perspectives in a single testing and investigation of a few times in a single testing, which can accomplish the most efficient expense and the data value execution proportion. Simultaneously, genomics information can likewise be utilized as a fortune trove of data, aggregating important assets for further therapeutic research.

4. References

1. Zhang Y, Wang F, Cen X, Hongxing L (2015) Mutaome profile of 10 common mutated genes in refractory and relapsed acute myeloid leukemia. *J Leuk Lymph* 24: 261-264.
2. Wang F, Zhang Y, Chen X, Hongxing L (2015) Mutaome analysis including 10 common mutated genes in newly diagnosed acute myeloid leukemia patients. *J Leuk Lymph* 24: 161-164.
3. Liu M, Zhang Y, Wang F, Chen Xue, Nie D, et al. (2017) Mutaome analysis of common mutated genes in patients with myelodysplastic syndromes. *J Clin Path Res* 37: 2332-2338.
4. Zhang Y, Liu M, Liu HX (2017) Gene mutations and its clinical significance in myelodysplastic syndrome. *J Clin Path Res* 37: 2237-2242.
5. West AH, Churpek JE (2017) Old and new tools in the clinical diagnosis of inherited bone marrow failure syndromes. *Hematol Am Soc Hematol Educ Prog* 2: 79-87.
6. Arber DA, Orazi A, Hasserjian R (2016) The 2016 revision to the world health organization classification of myeloid neoplasms and acute leukemia. *Blood* 127: 2391-2405.
7. Liu HX, Zhou FY, Zhang Y (2016) Advances in personalized medicine of hematologic neoplasms and related pharmacogenetics. *J Leuk Lymph* 25: 385-388.
8. Roy DC, Perreault C (2017) Major vs minor histocompatibility antigens. *Blood* 129: 664-666.
9. Efremova M, Finotello F, Rieder D, Trajanoski Z (2017) Neoantigens generated by individual mutations and their role in cancer immunity and immunotherapy. *Front Immunol* 28:1679.
10. Liu HX, Zhang Y, Chen X (2017) Advances in telomere and telomerase in hematological diseases. *J Leuk Lymph* 25: 12-14.
11. Lee M, Napier CE, Yang SF, Reddel RR, Pickett HA, et al. (2017) Comparative analysis of whole genome sequencing-based telomere length measurement techniques. *Methods* 114: 4-15.



This work is licensed under a Creative Commons Attribution Non-Commercial 4.0 International License.